Geneva University Hospitals / Hôpitaux universitaires de Genève (HUG)

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study (2019) Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, et al. Journal article Analysis of the influence of microRNAs in lithium response in bipolar disorder (2018) Reinbold CS, Forstner AJ, Hecker J, Fullerton JM, Hoffmann P, Hou L, Heilbronner U, et al. Journal article Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder: A genome-wide association study (2018) Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Heilbronner U, Degenhardt F, et al. Journal article European expert consensus statement on therapeutic goals in Fabry disease (2018) Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, et al. Journal article Prevalence of the apolipoprotein E ?4 allele in amyloid ? positive subjects across the spectrum of Alzheimer's disease (2018) Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, et al. Journal article Neurons under T Cell Attack Coordinate Phagocyte-Mediated Synaptic Stripping (2018) Di Liberto G, Pantelyushin S, Kreutzfeldt M, Page N, Musardo S, Coras R, Steinbach K, et al. Journal article Pitfalls in the measurement of muscle mass: a need for a reference standard (2018) Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, Maggi S, et al. Journal article The authors reply: Letter on: "Pitfalls in the measurement of muscle mass: a need for a reference standard" by Clark et al (2018) Buckinx F, Landi F, Cesari M, Fieding RA, Visser M, Engelke K, Maggi S, et al. Journal article, Letter The Authors reply: "Dual energy X-ray absorptiometry: gold standard for muscle mass?" by Scafoglieri et al (2018) Buckinx F, Landi F, Cesari M, Fieding RA, Visser M, Engelke K, Maggi S, et al. Journal article, Note Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease (2018) Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Koetter I, Hachulla E, et al. Journal article